New antibiotics for gram positive infections: linezolid and combination quinapristin/dalfopristin.
Considerable research over the past decade has thrown up two novel antibiotic preparations which are effective in 'difficult' Gram positive infections. Their imminent arrival is welcomed at a time when the emergence of resistance to last line drugs is rapidly spreading. Their careful use is, however, crucial if long-term value is to be preserved.
MacConnachie
A M
AM
D000081:Acetamides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D011307:Drug Prescriptions; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D000069349:Linezolid; D010080:Oxazoles / Q000627:therapeutic use*; D023303:Oxazolidinones; D012449:Safety; D014769:Virginiamycin / Q000627:therapeutic use*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D010080:Oxazoles; D023303:Oxazolidinones; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D000069349:Linezolid